LCM
FATE icon

Laurion Capital Management’s Fate Therapeutics FATE Stock Holding History

Laurion Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35,173
Closed -$74.6K – 524
2023
Q3 		$74.6K Buy
35,173
+19,787
+129% +$65.6K ﹤0.01% 455
2023
Q2 		$73.2K Buy
+15,386
New +$84.9K ﹤0.01% 544
2022
Q2 		– Sell
-11,950
Closed -$463K – 554
2022
Q1 		$463K Buy
+11,950
New +$463K 0.01% 378

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Laurion Capital Management's FATE Position: Q4 2023 in Review

Laurion Capital Management sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 35,173 shares — an estimated $74.6K sold.

Laurion Capital Management first reported a position in FATE in Q1 2022 and held it in 3 quarters. The position peaked at $463K in Q1 2022. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Laurion Capital Management reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Laurion Capital Management sold 35,173 Fate Therapeutics shares in Q4 2023, an estimated $74.6K.
  • Laurion Capital Management first reported a position in Fate Therapeutics in Q1 2022 and held it in 3 quarters.
  • Laurion Capital Management's Fate Therapeutics position peaked at $463K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Laurion Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.